Antibody composition-producing cell

• US 20030115614A1
• Filed: 10/09/2001
• Published: 06/19/2003
• Est. Priority Date: 10/06/2000
• Status: Active Grant

• Current Assignee: Kyowa Kirin Co., Ltd. (Kirin Holdings Company Limited)
• Original Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited)
• Inventors: Shinkawa, Toyohide, Yamane, Naoko, Uchida, Kazuhisa, Yamasaki, Motoo, Yamano, Kazuya, Satoh, Mitsuo, Nakamura, Kazuyasu, Hanai, Nobuo, Kanda, Yutaka, Hosaka, Emi
• Granted Patent: US 6,946,292 B2
• Time in Patent Office: Days
• US Class Current: 800/6
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/1063 env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/2812 against CD4
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 : Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/8245 : involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
• CPC Class Codes: C12N 15/8257 : for the production of primary gene products, e.g. pharmaceutical products, interferon
• CPC Class Codes: C12N 15/8258 : for the production of oral vaccines (antigens) or immunoglobulins
• CPC Class Codes: C12N 9/0006 : acting on CH-OH groups as donors (1.1)
• CPC Class Codes: C12N 9/1051 : Hexosyltransferases (2.4.1)
• CPC Class Codes: C12N 9/90 : Isomerases (5.)
• CPC Class Codes: C12P 21/00 : Preparation of peptides or proteins single cell protein C12N1/00
• CPC Class Codes: C12P 21/005 : Glycopeptides, glycoproteins
• CPC Class Codes: C12Y 204/01068 : Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8

Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Claims

1. A Chinese hamster ovary tissue-derived CHO cell into which a gene encoding an antibody molecule is introduced, which produces an antibody composition comprising an antibody molecule having complex N-glycoside-linked sugar chains bound to the Fc region, wherein among the total complex N-glycoside-linked sugar chains bound to the Fc region in the composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is 20% or more.

2. The CHO cell according to claim 1, wherein the sugar chain to which fucose is not bound is a complex N-glycoside-linked sugar chain in which 1-position of fucose is not bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond.

3. The CHO cell according to claim 1 or 2, wherein the antibody molecule belongs to an IgG class.

4. The CHO cell according to any one of claims 1 to 3, wherein the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the complex N-glycoside-linked sugar chain is decreased or deleted.

5. The CHO cell according to claim 4, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

(a) GMD (GDP-mannose 4,6-dehydratase);

(b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);

(c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

6. The CHO cell according to claim 5, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

65;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

65 under stringent conditions and encodes a protein having GMD activity.

7. The CHO cell according to claim 5, wherein the GMD is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

71 and has GMD activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

71 and has GMD activity.

8. The CHO cell according to claim 5, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

48;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

48 under stringent conditions and encodes a protein having Fx activity.

9. The CHO cell according to claim 5, wherein the Fx is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

72;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

72 and has Fx activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

72 and has Fx activity.

10. The CHO cell according to claim 5, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

51;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

51 under stringent conditions and encodes a protein having GFPP activity.

11. The CHO cell according to claim 5, wherein the GFPP is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

73;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

73 and has GFPP activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

73 and has GFPP activity.

12. The CHO cell according to claim 4, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of the N-acetylglucosamine in the reducing end through α

-bond in the complex N-glycoside-linked sugar chain is α

-1,6-fucosyltransferase.

13. The CHO cell according to claim 12, wherein the α

-1,6-fucosyltransferase is a protein encoded by a DNA of the following (a) or (b);

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

1;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

1 under stringent conditions and encodes a protein having α

-1,6-fucosyltransferase activity.

14. The CHO cell according to claim 12, wherein the α

-1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b) and (c);

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

23;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

23 and has α

-1,6-fucosyltransferase activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

23 and has α

-1,6-fucosyltransferase activity.

15. The CHO cell according to any one of claims 4 to 14, wherein the enzyme activity is decreased or deleted by a technique selected from the group consisting of the following (a), (b), (c), (d) and (e):

(a) a gene disruption technique targeting a gene encoding the enzyme;

(b) a technique for introducing a dominant negative mutant of a gene encoding the enzyme;

(c) a technique for introducing mutation into the enzyme;

(d) a technique for inhibiting transcription and/or translation of a gene encoding the enzyme;

(e) a technique for selecting a cell line resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the complex N-glycoside-linked sugar chain.

16. The CHO cell according to any one of claims 4 to 15, which is resistant to at least a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the complex N-glycoside-linked sugar chain.

17. The CHO cell according to any one of claims 4 to 16, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition produced by its parent CHO cell.

18. The CHO cell according to claim 17, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition in which among the total complex N-glycoside-linked sugar chains bound to the Fc region contained in the antibody composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is less than 20%.

19. The CHO cell according to claim 18, wherein the sugar chain to which fucose is not bound is a complex N-glycoside-linked sugar chain in which 1-position of the fucose is not bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond.

20. A method for producing an antibody composition, which comprises culturing the CHO cell according to any one of claims 1 to 19 in a medium to produce and accumulate an antibody composition in the culture;

and recovering the antibody composition from the culture.

21. An antibody composition which is produced using the method according to claim 20.

55. A medicament comprising the antibody composition according to any one of claims 21, 22, 41 and 54 as an active ingredient.

56. The medicament according to claim 55, wherein the medicament is a diagnostic drug, a preventive drug or a therapeutic drug for diseases accompanied by tumors, diseases accompanied by allergies, diseases accompanied by inflammations, autoimmune diseases, circulatory organ diseases, diseases accompanied by viral infections or diseases accompanied by bacterial infections.

22. An antibody composition which comprises an antibody molecule having complex N-glycoside-linked sugar chains bound to the Fc region which is produced by a CHO cell, wherein among the total complex N-glycoside-linked sugar chains bound to the Fc region in the composition, the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain is 20% or more.

23. A cell in which the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain wherein 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the complex N-glycoside-linked sugar chain is decreased or deleted by a genetic engineering technique.

24. The cell according to claim 23, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

(a) GMD (GDP-mannose 4,6-dehydratase);

(b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);

(c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

25. The cell according to claim 24, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

65;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

65 under stringent conditions and encodes a protein having GMD activity.

26. The cell according to claim 24, wherein the GMD is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

71 and has GMD activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

71 and has GMD activity.

27. The cell according to claim 24, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

48;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

48 under stringent conditions and encodes a protein having Fx activity.

28. The cell according to claim 24, wherein the Fx is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

72;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

72 and has Fx activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

72 and has Fx activity.

29. The cell according to claim 24, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

51;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

51 under stringent conditions and encodes a protein having GFPP activity.

30. The cell according to claim 24, wherein the GFPP is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

73;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

73 and has GFPP activity;

(c) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

73 and has GFPP activity.

31. The cell according to claim 23, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the N-glycoside-linked sugar chain is α

-1,6-fucosyltransferase.

32. The cell according to claim 31, wherein the α

-1,6-fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the following (a), (b), (c) and (d);

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

1;

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

2;

(c) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

1 under stringent conditions and encodes a protein having α

-1,6-fucosyltransferase activity,;

(d) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

2 under stringent conditions and encodes a protein having α

-1,6-fucosyltransferase activity.

33. The cell according to claim 31, wherein the α

-1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b), (c), (d), (e) and (f);

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

23;

(b) a protein comprising the amino acid sequence represented by SEQ ID NO;

24;

(c) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

23 and has α

-1,6-fucosyltransferase activity;

(d) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

24 and has α

-1,6-fucosyltransferase activity;

(e) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

23 and has α

-1,6-fucosyltransferase activity;

(f) a protein which comprises an amino acid sequence having a homology of at least 80% with the amino acid sequence represented by SEQ ID NO;

24 and has α

-1,6-fucosyltransferase activity.

34. The cell according to any one of claims 23 to 33, wherein the genetic engineering technique is a technique selected from the group consisting of the following (a), (b), (c) and (d):

(a) a gene disruption technique targeting a gene encoding the enzyme;

(b) a technique for introducing a dominant negative mutant of a gene encoding the enzyme;

(c) a technique for introducing mutation into the enzyme;

(d) a technique for inhibiting transcription and/or translation of a gene encoding the enzyme.

35. The cell according to any one of claims 23 to 34, which is resistant to at least a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the N-glycoside-linked sugar chain.

36. The cell according to any one of claims 23 to 35, which is a cell selected from the group consisting of the following (a) to (i):

(a) a CHO cell derived from a Chinese hamster ovary tissue;

(b) a rat myeloma cell line, YB2/3HL.P2.G11.16Ag.20 cell;

(c) a mouse myeloma cell line, NSO cell;

(d) a mouse myeloma cell line, SP2/0-Ag14 cell;

(e) a BHK cell derived from a syrian hamster kidney tissue;

(f) an antibody-producing hybridoma cell;

(g) a human leukemia cell line Namalwa cell;

(h) an embryonic stem cell;

(i) a fertilized egg cell.

37. The cell according to any one of claims 23 to 36 into which a gene encoding an antibody molecule is introduced.

38. The cell according to claim 37, wherein the antibody molecule belongs to an IgG class.

39. A method for producing an antibody composition, which comprises culturing the cell according to claim 37 or 38 in a medium to produce and accumulate the antibody composition in the culture;

and recovering the antibody composition from the culture.

40. The method according to claim 39, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition obtained from its parent cell line.

41. An antibody composition which is produced using the method according to claim 39 or 40.

42. A transgenic non-human animal or plant or the progenies thereof, comprising a genome which is modified such that the activity of an enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose and/or the activity of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the N-glycoside-linked sugar chain is decreased.

43. The transgenic non-human animal or plant or the progenies thereof according to claim 42, wherein a gene encoding the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose or a gene encoding the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the N-glycoside-linked sugar chain is knocked out.

44. The transgenic non-human animal or plant or the progenies thereof according to claim 42 or 43, wherein the enzyme relating to the synthesis of an intracellular sugar nucleotide, GDP-fucose is an enzyme selected from the group consisting of the following (a), (b) and (c):

(a) GMD (GDP-mannose 4,6-dehydratase);

(b) Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase);

(c) GFPP (GDP-beta-L-fucose pyrophosphorylase).

45. The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the GMD is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

65;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

65 under stringent conditions and encodes a protein having GMD activity.

46. The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the Fx is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

48;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

48 under stringent conditions and encodes a protein having Fx activity.

47. The transgenic non-human animal or plant or the progenies thereof according to claim 44, wherein the GFPP is a protein encoded by a DNA of the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

51;

(b) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

51 under stringent conditions and encodes a protein having GFPP activity.

48. The transgenic non-human animal or plant or the progenies thereof according to claim 42 or 43, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α

-bond in the N-glycoside-linked sugar chain is α

-1,6-fucosyltransferase.

49. The transgenic non-human animal or plant or the progenies thereof according to claim 48, wherein the α

-1,6-fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the following (a), (b), (c) and (d);

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

1;

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

2;

(c) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

1 under stringent conditions and encodes a protein having α

-1,6-fucosyltransferase activity;

(d) a DNA which hybridizes with the DNA comprising the nucleotide sequence represented by SEQ ID NO;

2 under stringent conditions and encodes a protein having α

-1,6-fucosyltransferase activity.

50. The transgenic non-human animal or plant or the progenies thereof according to any one of claims 42 to 49, wherein the transgenic non-human animal is an animal selected from the group consisting of cattle, sheep, goat, pig, horse, mouse, rat, fowl, monkey and rabbit.

51. A method for producing an antibody composition, which comprises introducing a gene encoding an antibody molecule into the transgenic non-human animal or plant or the progenies thereof according to any one of claims 42 to 50;

rearing the animal or plant;

isolating tissue or body fluid comprising the introduced antibody from the reared animal or plant; and

recovering the antibody composition from the isolated tissue or body fluid.

52. The method according to claim 51, wherein the antibody molecule belongs to an IgG class.

53. The method according to claim 51 or 52, which produces an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition obtained from a non-human animal or plant or the progenies thereof whose genome is not modified.

54. An antibody composition which is produced using the method according to any one of claims 51 to 53.

57. A protein selected from the group consisting of the following (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO;

71;

(b) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

71 and has GMD activity;

(c) a protein comprising the amino acid sequence represented by SEQ ID NO;

72;

(d) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

72 and has Fx activity;

(e) a protein comprising the amino acid sequence represented by SEQ ID NO;

73;

(f) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

73 and has GFPP activity;

(g) a protein comprising the amino acid sequence represented by SEQ ID NO;

23;

(h) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

23 and has α

-1,6-fucosyltransferase activity;

(i) a protein comprising the amino acid sequence represented by SEQ ID NO;

24;

(j) a protein which comprises an amino acid sequence in which at least one amino acid is deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO;

24 and the α

-1,6-fucosyltransferase activity.

58. A DNA which encodes the protein according to claim 57.

61. A target vector for homologous recombination, comprising a full length of the DNA according to any one of claims 58 to 60, or a part thereof.

59. A DNA selected from the group consisting of the following (a), (b), (c), (d) and (e):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

1;

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

2;

(c) a DNA comprising the nucleotide sequence represented by SEQ ID NO 65;

(d) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

48;

(e) a DNA comprising the nucleotide sequence represented by SEQ ID NO;

51.

60. A genome DNA selected from the group consisting of the following (a), (b) and (c):

(a) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO;

3;

(b) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO;

67;

(c) a genome DNA comprising the nucleotide sequence represented by SEQ ID NO;

70.